Kalray Announces the Availability of Its TURBOCARD4 Card: a Paradigm Shift in Compute Acceleration for Smart Vision and Gen-AI Data-indexing Applications
2.4.2024 19:57:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software solutions to accelerate data intensive workflows from Cloud to Edge announces the commercial availability of its latest product, the TURBOCARD4 (TC4) acceleration card. Powered by four of Kalray’s latest generation of DPU processors, the TC4 targets the fast growing markets of AI-powered smart vision and data-indexing applications. The TC4 is manufactured in France, in the French plant of Asteelflash, one of the leading global manufacturers worldwide. Kalray already received an initial order of more than $1 million (hundreds of cards) 1 to be recognized this year.
TC4 TARGETS THE FAST GROWING COMPUTE ACCELERATION CARD MARKET
Whereas enterprises and data centers have to process an ever-growing amount of data, compute acceleration cards are getting more and more traction to bring the best performance and best power efficiency in data processing.
“The availability of our new TC4 acceleration card is a major step for Kalray to set the stage for the widespread adoption of our latest acceleration technology. The TC4 has already been selected by one of our major customers and we envision a fast commercial take-off due to the ever-increasing demand in data processing acceleration solutions”, shares Eric Baissus, Kalray CEO.
“In addition, we are very proud to announce that the TC4 is our first “made in France” product. The production is ramping up rapidly in the plant of the leading global manufacturer AsteelFlash in Langon”.
BUILT TO COMBINE AI AND CLASSICAL COMPUTING
TC4 embodies Kalray's vision in addressing the intricate demands of modern computing workloads. Housing four of the latest generation of Kalray’s DPUs, Coolidge2TM, in a single PCIe card, Kalray’s TC4 is designed to ensure customers can merge classical and AI-based processing technologies and create superior, efficiency-driven systems for the most processing-intensive AI applications. DPUs offer a very complementary architecture to GPUs, allowing for the processing of a large number of different operations in parallel in an asynchronous way. DPUs are well-suited for pre-processing data that is later used by GPUs or in the context of complex intelligent systems running many different algorithms in parallel.
TWO FAST GROWING MARKETS TARGETTED: THE SMART VISION MARKET…
TC4 is strategically targeted at two rapidly growing markets. The first one is the Smart Vision market. Smart vision applications play a pivotal role in transformative sectors such as Industrial, Health Science, or Smart City operations due to their ability to analyze visual data in real-time, make intelligent decisions, and automate complex processes. The smart vision market size was valued at USD 20.31 billion in 2023 which is forecasted to reach USD 175.72 billion by 2032, exhibiting a CAGR of 27.3% (Fortune Business Insights). These projections highlight the increasing demand of smart vision technologies across various industries, driven by advancements in AI and machine learning, and their application in automation, quality control, and enhanced operational efficiencies.
…AND THE DATA-INDEXING FOR GEN-AI MARKET
In the context of Generative AI, data indexing is crucial for several reasons. Generative AI models, such as those used in natural language processing or image generation, often need to access enormous datasets. Efficient indexing minimizes the time required to fetch the relevant data, making the training and inference processes faster.
In addition, as Generative AI models become more complex, the datasets they train on grow exponentially. Data indexing allows these models to scale more effectively by ensuring that the increase in data volume does not linearly increase access times.
Data-Indexing also improves models’ outputs accuracy as indexing helps quickly identify the most relevant data pieces to insert in model context and prompt. This ensures that the model's outputs are as accurate and contextually appropriate as possible.
TC4 PRODUCTION HAS BEEN RE-LOCATED TO ASTEELFLASH FRENCH PLANT
Kalray's commitment to quality and desire to re-locate its production to Europe led to the alliance with Asteelflash for TC4 production. Asteelflash is one of the leading global electronic manufacturing services (EMS) companies, specializing in complex and high-tech manufacturing solutions across various industries. Asteelflash has several plants in Europe, including Germany and France. The TC4 production is performed in the Langon, France plant. This partnership has been supported by the French government as part of the CARAIBE funded project. The production volume is expected to grow from a few hundred per month today to several thousands of units per month, starting in 2025.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Sciences, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
1 See press release as of 11th January, 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402257071/en/
Contact information
INVESTOR
E
ric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone +33 4 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone + 33 1 53 67 36 72
PRESS
P
enta STANLEY
communication@kalrayinc.com
Phone +44 7939 877 880
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone +33 4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 14:12:00 EEST | Press release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
SLB Announces Third-Quarter 2026 Results23.10.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 12:58:00 EEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets.8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide. Relfydess is the first and only ready-to-use liquid neuromodulator developed with PEARL Technology, designed to deliver a highly active, innovative, complex-free molecule that addresses the real needs of patients and healthcare professionals.1,2,4,5 It is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.1,10 At a time whenpatients and healthcare professionals are increasingly seeking high-performance neuromodulators that rapidly deliver long-lasting, natural-looking outcomes, Re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
